Serum markers detect the presence of liver fibrosis: a cohort study.
By W. Rosenberg, M. Voelker, R. Thiel, M. Becka, A. Burt, D. Schuppan, S. Hubscher, T. Roskams, M. Pinzani, M. Arthur. Gastroenterology, 2004
1,146 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/9e2d27a6ac74631a37f291a1a734eb4a8d44a2a9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- C. Day
- Asociacion Latinoamericana para el Estudio del Higado
- Nimantha Mark Wilfred de Alwis
- L. Adams
- G. Targher
In Hepatology
Citations in the corpus
- Non-alcoholic fatty liver disease: the mist gradually clears. (2008, methodology): “This score has recently been combined with the European Liver Fibrosis (ELF) panel of serum fibrosis markers [53] and shown to have an accuracy of over 90% in differentiating different fibrosis stages in NAFLD [54].”
- Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. (2005, background): “Many published studies have also developed panels of serum markers applicable to fibrosis prediction in hepatitis C–infected patients (13, 15, 16, 19, 26, 27); however, our study has several unique features.”
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007, neutral): “5 19 (14-25) 98 (97-100) 64 (53-75) 97 (95-98) 10 33 (26-39) 97 (95-99) 78 (68-87) 94 (91-96) 15 42 (35-49) 96 (93-98) 84 (76-93) 91 (88-94) 20 49 (42-56) 94 (91-97) 88 (80-95) 88 (85-91) 25 55 (47-62) 93 (90-96) 90 (83-97) 86 (82-89) 30 59 (52-66) 92 (88-95) 91 (85-98) 83 (80-87) 35 63 (56-70) 90 (”
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “Journal of Hepatology 201 Recommendations • TE may be used to rule out severe fibrosis or cirrhosis in patients with ALD (B2) • Non-invasive assessment of fibrosis, using TE should be considered in patients with PBC or PSC (B2) • Follow-up assessment of liver fibrosis with TE should be performed in ”